[Carboplatin-etoposide-bleomycine chemotherapy protocol in the treatment of patients with metastatic non-seminomatous germ-cell testicular tumours with good prognosis].
Fifteen patients with metastatic non-seminomatous germ-cell tumours with good prognosis were treated with carboplatin-etoposide-bleomycine chemotherapy. Patients were followed-up from 8 to 56 months (median 32 months). In 13 patients there was no evidence of the disease and in 2 patients recurred, but recovered after the subsequent secondary chemotherapy (cisplatin-bleomycine-vincristine). Signs and symptoms of toxicity included alopecia in 93% of patients, nausea and vomiting in 40%, while in respect of haematological toxicity, leucopenia was observed in all 15 patients, thrombocytopenia in 80%, and decrease of haemoglobinaemia in 60% of patients. Other toxicities were not observed. Carboplatin-etoposide-bleomycine chemotherapy is effective and little toxic, but a greater number of patients and a longer follow-up are needed for definitive evaluatin of this therapy in the treatment of patients with metastatic non-seminomatous germ-cell testicular tumours with good prognosis.
Jeremić
B
B
Djurić
Lj
Lj
Djordjević
S
S
Cirović
V
V
Milojević
Lj
Lj
Stanisavljević
B
B
Matović
M
M
Mijatović
Lj
Lj
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D016190:Carboplatin; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*; D011379:Prognosis; D013736:Testicular Neoplasms / Q000188:drug therapy*
D001761:Bleomycin; D005047:Etoposide; D016190:Carboplatin